| 201 |
17905465 | ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. | 2008 Mar |
4 |
| 202 |
17953711 | Clinical relevance of the homologous recombination machinery in cancer therapy. | 2008 Feb |
2 |
| 203 |
18231104 | Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. | 2008 Feb 26 |
1 |
| 204 |
18347182 | Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. | 2008 Mar 15 |
2 |
| 205 |
18402708 | ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. | 2008 Apr 11 |
6 |
| 206 |
18425336 | ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy. | 2008 May |
1 |
| 207 |
18483312 | Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1. | 2008 May |
1 |
| 208 |
18594541 | ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. | 2008 Jul 8 |
3 |
| 209 |
18623378 | ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. | 2008 Sep 15 |
2 |
| 210 |
18640939 | Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. | 2008 Jul 20 |
1 |
| 211 |
18645262 | Upregulation of ZNRD1 enhances cisplatin resistance in human esophageal cancer cells by regulation of ERCC1 and Bcl-2. | 2008 |
1 |
| 212 |
18756932 | [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer]. | 2008 Mar |
10 |
| 213 |
18827563 | Activity of lipoplatin in tumor and in normal cells in vitro. | 2008 Nov |
1 |
| 214 |
19080461 | [RNA interference silencing excision repair cross-complementing 1 gene and affecting cisplatin sensitivity on lung cancer cell lines]. | 2008 Oct 28 |
3 |
| 215 |
19578506 | Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer. | 2008 Apr 17 |
4 |
| 216 |
21885003 | Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancer. | 2008 Mar |
1 |
| 217 |
17151930 | Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-à-vis chemotherapy drug cytotoxicity in human glioma. | 2007 May |
3 |
| 218 |
17229776 | Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. | 2007 Mar |
1 |
| 219 |
17489733 | Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. | 2007 May |
1 |
| 220 |
17534174 | ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. | 2007 Jul |
3 |
| 221 |
17600754 | Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. | 2007 |
1 |
| 222 |
17602080 | Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. | 2007 Jul 1 |
5 |
| 223 |
17606717 | Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. | 2007 Jul 1 |
4 |
| 224 |
17607914 | Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. | 2007 |
1 |
| 225 |
17686445 | How could pharmacogenomics help improve patient survival? | 2007 Aug |
1 |
| 226 |
18157593 | [Biomarkers - the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC)]. | 2007 |
2 |
| 227 |
18235415 | [Predicting the response to chemotherapy in patients with non-small cell lung cancer]. | 2007 Oct |
1 |
| 228 |
19190690 | ERCC1 Expression in Diffuse Large B-Cell Lymphoma Patients Treated with a Cisplatin-Based Regimen : A Brief Communication. | 2007 Sep |
4 |
| 229 |
21126401 | [Relationship between ERCC1 expression and cisplatin intervention in human lung adenocarcinoma cell lines]. | 2007 Oct 20 |
15 |
| 230 |
16426580 | MZF1 possesses a repressively regulatory function in ERCC1 expression. | 2006 Mar 14 |
4 |
| 231 |
16462182 | Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. | 2006 Mar |
1 |
| 232 |
16632419 | From the bench to the bed: individualizing treatment in non-small-cell lung cancer. | 2006 Feb |
1 |
| 233 |
16690105 | Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines. | 2006 Nov |
2 |
| 234 |
16756962 | XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair. | 2006 Jul 14 |
4 |
| 235 |
16762192 | [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines]. | 2006 May |
3 |
| 236 |
16765644 | Predicting the outcome of chemotherapy for lung cancer. | 2006 Aug |
1 |
| 237 |
16935774 | Usefulness of predictive tests for cancer treatment. | 2006 Aug |
1 |
| 238 |
16957145 | DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. | 2006 Sep 7 |
3 |
| 239 |
16980606 | ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. | 2006 Dec |
4 |
| 240 |
17163161 | Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. | 2006 |
1 |
| 241 |
17303907 | Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. | 2006 |
2 |
| 242 |
19771254 | Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer. | 2006 Feb |
7 |
| 243 |
15629453 | Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. | 2005 Feb 4 |
9 |
| 244 |
15688021 | Expression of a splicing variant in the 5'-UTR of the human ERCC1 gene is not cancer related. | 2005 Mar 17 |
3 |
| 245 |
16551521 | Applications of genomics in NSCLC. | 2005 Dec |
2 |
| 246 |
16557672 | Applications of genomics in NSCLC. | 2005 Dec |
2 |
| 247 |
14706347 | Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells. | 2004 Feb 3 |
4 |
| 248 |
14977831 | Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. | 2004 Feb 15 |
2 |
| 249 |
14981577 | Molecular predictors of response to chemotherapy in lung cancer. | 2004 Feb |
2 |
| 250 |
15140544 | Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. | 2004 Jun |
2 |